FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2052122168> ?p ?o ?g. }

• W2052122168 endingPage "56" @default.
• W2052122168 startingPage "50" @default.
• W2052122168 abstract "Objective To evaluate the efficacy and tolerability of doxazosin in the treatment of bladder outflow obstruction resulting from benign prostatic hyperplasia (BPH). Patients and methods One-hundred and thrity-five patients with symptomatic urodynamicaly confirmed obstructive BPH ware treated for 12 weeks with either doxazosin (67 patients) or placebo (68 patients) after an initial 2 week baseline evaluation. The main outcome measures were urodynamic and symptomatic evaluation for efficacy. Blook pressre and adverse events were monitored. Results Date were obtained in 122 patients (60 doxazosin, 62 placebo). Doxazosin produced increases in both mean and maximum urinary flow rates of 1.01 ml/s and 3.2 ml/s rspectively, compared with 0.21 ml/s and 2.2 ml/s on placebo. The increase in mean flow rate was statistically significant (P=0.04). While that for maximun flow rate approached significance (P= 0.09). The maximum subracted voiding pressure was substantially reduced (P=0.007) and 19 of 53 (36%) patients had an increase in maximum flow rate of 50% or more compared with 9 of 54 (17%) on placebo (P=0.024). Twelve weeks' therapy with doxaosin resulted in significant improvements (compared with placebo) in: hesitancy 9doxazosin 26 of 46. placebo 11 of 43; P=0.003), impaired urinary stream (doxazosin 31 of 55, placebo 16 of 48; P=0.019). nocturia (doxazoshin 22 of 56, placebo 10 of 54; P=0.017) and urgency (doxazosin 27 of 45, placebo 16 of 42; P=0.041). Frequency improved with doxazosin therapy (doxazosin 26 of 59, placebo 15 of 55; P=0.062). Adverse events, most frequenly dizziness and headache, were usually mild and transient and led to a discontinuation of doxazosin therapy in one patient. No clinically significant changes in sexual function or blood pressure were seen. Conclusion Doxazosin was well-tolerated and produced both urodynamic and symptomatic improvement in men with BPH. thereby providing a satisfactory alterntive to existing drugs with the additional benefit of one dily dosage." @default.
• W2052122168 created "2016-06-24" @default.
• W2052122168 creator A5001479798 @default.
• W2052122168 creator A5010461248 @default.
• W2052122168 creator A5012831578 @default.
• W2052122168 creator A5033230933 @default.
• W2052122168 creator A5036463446 @default.
• W2052122168 creator A5080266362 @default.
• W2052122168 creator A5085623077 @default.
• W2052122168 date "1994-07-01" @default.
• W2052122168 modified "2023-10-18" @default.
• W2052122168 title "A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction" @default.
• W2052122168 cites W125951672 @default.
• W2052122168 cites W1980245302 @default.
• W2052122168 cites W1980371594 @default.
• W2052122168 cites W198934061 @default.
• W2052122168 cites W1992518331 @default.
• W2052122168 cites W1999783560 @default.
• W2052122168 cites W2000489906 @default.
• W2052122168 cites W2026238971 @default.
• W2052122168 cites W2028318610 @default.
• W2052122168 cites W2038819520 @default.
• W2052122168 cites W2042486803 @default.
• W2052122168 cites W2050670825 @default.
• W2052122168 cites W2064143963 @default.
• W2052122168 cites W2067041008 @default.
• W2052122168 cites W2067682956 @default.
• W2052122168 cites W2077512799 @default.
• W2052122168 cites W2090295903 @default.
• W2052122168 cites W2094977125 @default.
• W2052122168 cites W2097962665 @default.
• W2052122168 cites W2104580244 @default.
• W2052122168 cites W2132135021 @default.
• W2052122168 cites W2144563350 @default.
• W2052122168 cites W2151204574 @default.
• W2052122168 cites W2341507669 @default.
• W2052122168 cites W2395575737 @default.
• W2052122168 cites W2400484695 @default.
• W2052122168 cites W2419306660 @default.
• W2052122168 cites W4289655 @default.
• W2052122168 doi "https://doi.org/10.1111/j.1464-410x.1994.tb16546.x" @default.
• W2052122168 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7519112" @default.
• W2052122168 hasPublicationYear "1994" @default.
• W2052122168 type Work @default.
• W2052122168 sameAs 2052122168 @default.
• W2052122168 citedByCount "115" @default.
• W2052122168 countsByYear W20521221682012 @default.
• W2052122168 countsByYear W20521221682014 @default.
• W2052122168 countsByYear W20521221682015 @default.
• W2052122168 countsByYear W20521221682016 @default.
• W2052122168 countsByYear W20521221682017 @default.
• W2052122168 countsByYear W20521221682019 @default.
• W2052122168 countsByYear W20521221682022 @default.
• W2052122168 crossrefType "journal-article" @default.
• W2052122168 hasAuthorship W2052122168A5001479798 @default.
• W2052122168 hasAuthorship W2052122168A5010461248 @default.
• W2052122168 hasAuthorship W2052122168A5012831578 @default.
• W2052122168 hasAuthorship W2052122168A5033230933 @default.
• W2052122168 hasAuthorship W2052122168A5036463446 @default.
• W2052122168 hasAuthorship W2052122168A5080266362 @default.
• W2052122168 hasAuthorship W2052122168A5085623077 @default.
• W2052122168 hasConcept C121608353 @default.
• W2052122168 hasConcept C126322002 @default.
• W2052122168 hasConcept C126894567 @default.
• W2052122168 hasConcept C142724271 @default.
• W2052122168 hasConcept C197934379 @default.
• W2052122168 hasConcept C204787440 @default.
• W2052122168 hasConcept C27081682 @default.
• W2052122168 hasConcept C2776235491 @default.
• W2052122168 hasConcept C2777333188 @default.
• W2052122168 hasConcept C2777562237 @default.
• W2052122168 hasConcept C2777590997 @default.
• W2052122168 hasConcept C2778375690 @default.
• W2052122168 hasConcept C2780070792 @default.
• W2052122168 hasConcept C71924100 @default.
• W2052122168 hasConcept C77411442 @default.
• W2052122168 hasConcept C84393581 @default.
• W2052122168 hasConceptScore W2052122168C121608353 @default.
• W2052122168 hasConceptScore W2052122168C126322002 @default.
• W2052122168 hasConceptScore W2052122168C126894567 @default.
• W2052122168 hasConceptScore W2052122168C142724271 @default.
• W2052122168 hasConceptScore W2052122168C197934379 @default.
• W2052122168 hasConceptScore W2052122168C204787440 @default.
• W2052122168 hasConceptScore W2052122168C27081682 @default.
• W2052122168 hasConceptScore W2052122168C2776235491 @default.
• W2052122168 hasConceptScore W2052122168C2777333188 @default.
• W2052122168 hasConceptScore W2052122168C2777562237 @default.
• W2052122168 hasConceptScore W2052122168C2777590997 @default.
• W2052122168 hasConceptScore W2052122168C2778375690 @default.
• W2052122168 hasConceptScore W2052122168C2780070792 @default.
• W2052122168 hasConceptScore W2052122168C71924100 @default.
• W2052122168 hasConceptScore W2052122168C77411442 @default.
• W2052122168 hasConceptScore W2052122168C84393581 @default.
• W2052122168 hasIssue "1" @default.
• W2052122168 hasLocation W20521221681 @default.
• W2052122168 hasLocation W20521221682 @default.
• W2052122168 hasOpenAccess W2052122168 @default.
• W2052122168 hasPrimaryLocation W20521221681 @default.

• next